AbbVie prices new rheumatoid arthritis drug at $59,000 a year
(Reuters) – AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising…
AbbVie prices new rheumatoid arthritis drug at $59,000/yr
(Reuters) – AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising…
AbbVie CFO Chase stepping down, to retire by mid-year 2019
(Reuters) – AbbVie Inc (ABBV.N) said on Friday that Chief Financial Officer William Chase is retiring in mid-2019 and named its controller, Robert Michael, his immediate successor as CFO. FILE…
EU approves fifth copy of AbbVie’s $18 billion drug Humira
LONDON (Reuters) – Europe has approved a fifth copy of AbbVie’s $18-billion-a-year biologic drug Humira – the world’s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech…
AbbVie, AndroGel partner owe $448 million in antitrust case: U.S. judge
(Reuters) – A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market…
AbbVie’s lung cancer drug data disappoints; shares slump
(Reuters) – AbbVie Inc’s experimental lung cancer drug data was not effective enough to seek a faster approval, in a setback to the company’s efforts to build its cancer drug…